Session

Safety and emergencies in lower GI disease (Posters)

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)
SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS
HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

PROTECTIVE EFFECTS OF SACCHAROMYCES BOULARDII CNCM I-745 AGAINST NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED INTESTINAL INJURY
PROTECTIVE EFFECTS OF SACCHAROMYCES BOULARDII CNCM I-745 AGAINST NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED INTESTINAL INJURY

RISK PREDICTION FOR ADVANCED NEOPLASIA USING LONGITUDINAL ADHERENCE MEASURES TO FECAL IMMUNOCHEMICAL TEST-BASED COLORECTAL CANCER SCREENING PROGRAMS
RISK PREDICTION FOR ADVANCED NEOPLASIA USING LONGITUDINAL ADHERENCE MEASURES TO FECAL IMMUNOCHEMICAL TEST-BASED COLORECTAL CANCER SCREENING PROGRAMS

LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS
LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

STOPPING 5-AMINOSALICYCLIC ACID IN PATIENTS WITH LONG-STANDING INACTIVE ULCERATIVE COLITIS IS NOT ASSOCIATED WITH AN INCREASED RISK OF RELAPSE: RESULTS FROM A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
STOPPING 5-AMINOSALICYCLIC ACID IN PATIENTS WITH LONG-STANDING INACTIVE ULCERATIVE COLITIS IS NOT ASSOCIATED WITH AN INCREASED RISK OF RELAPSE: RESULTS FROM A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

STOPPING 5-AMINOSALICYCLIC ACID IN PATIENTS WITH LONG-STANDING INACTIVE ULCERATIVE COLITIS IS NOT ASSOCIATED WITH AN INCREASED RISK OF RELAPSE: RESULTS FROM A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
STOPPING 5-AMINOSALICYCLIC ACID IN PATIENTS WITH LONG-STANDING INACTIVE ULCERATIVE COLITIS IS NOT ASSOCIATED WITH AN INCREASED RISK OF RELAPSE: RESULTS FROM A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Safety and emergencies in lower GI disease (Posters)  et al.

THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Safety and emergencies in lower GI disease (Posters)  et al.

LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS
LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

Safety and emergencies in lower GI disease (Posters)  et al.

RISK PREDICTION FOR ADVANCED NEOPLASIA USING LONGITUDINAL ADHERENCE MEASURES TO FECAL IMMUNOCHEMICAL TEST-BASED COLORECTAL CANCER SCREENING PROGRAMS
RISK PREDICTION FOR ADVANCED NEOPLASIA USING LONGITUDINAL ADHERENCE MEASURES TO FECAL IMMUNOCHEMICAL TEST-BASED COLORECTAL CANCER SCREENING PROGRAMS

Safety and emergencies in lower GI disease (Posters)  et al.

PROTECTIVE EFFECTS OF SACCHAROMYCES BOULARDII CNCM I-745 AGAINST NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED INTESTINAL INJURY
PROTECTIVE EFFECTS OF SACCHAROMYCES BOULARDII CNCM I-745 AGAINST NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED INTESTINAL INJURY

Safety and emergencies in lower GI disease (Posters)  et al.

HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS
HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

Safety and emergencies in lower GI disease (Posters)  et al.

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Safety and emergencies in lower GI disease (Posters)  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)
SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)

Safety and emergencies in lower GI disease (Posters)  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Safety and emergencies in lower GI disease (Posters)  et al.

Item 1 - 18 / 18
1